Biotransformation and pharmacokinetics of ethylmorphine after a single oral dose.

1. The pharmacokinetics of ethylmorphine after administration of a single dose of the cough mixture Cosylan were investigated in 10 healthy subjects. 2. The median urinary recovery of ethylmorphine and measured metabolites was 77% over 48 h. The median tmax of unchanged ethylmorphine was 45 min, and the terminal elimination t1/2 was 2 h. Ethylmorphine-6-glucuronide was found to be the major metabolite. 3. Two subjects had significantly lower urinary recovery (0.48 h) of morphine and morphine-glucuronides than the remainder. Furthermore, these two had urinary metabolic ratios (MRO) and partial metabolic clearances (CLmO) for O-deethylation of ethylmorphine tentatively classifying them phenotypically as poor metabolisers of the debrisoquine/sparteine type. 4. Genotyping for cytochrome P450 (CYP) 2D6 alleles revealed five homozygote (wt/wt) and five heterozygote subjects. Two subjects phenotypically classified as poor metabolisers were genotypically CYP2D6A/wt and CYP2D6D/wt, respectively. 5. Serum and urine samples taken more than 8 and 24 h after administration of ethyl-morphine respectively, contained morphine and morphine-glucuronides, but no ethylmorphine, ethylmorphine-6-glucuronide or (serum only) norethylmorphine. Norethylmorphine could be detected after hydrolysis of urine samples in all subjects. The urinary recovery of the active metabolites morphine and morphine-6-glucuronide after administration of ethylmorphine varied by a factor of 9 between individuals. 6. The wide variation in recovery of morphine and morphine-glucuronides after oral administration of ethylmorphine could not be explained simply by a difference in CYP2D6 genotype. Constitutional variation in other enzymatic pathways involved in ethylmorphine metabolism is probably crucial. Ratios of morphine to parent drug cannot be used to distinguish the source of morphine after administration of ethylmorphine. Norethylmorphine should be included in urine assays for opiates in forensic toxicology, and no firm conclusions about the source of morphine are possible based on serum samples obtained more than 24 h after drug administration.

[1]  H. Gjerde,et al.  Evaluation of a method for simultaneous quantification of codeine, ethylmorphine and morphine in blood. , 1991, Forensic science international.

[2]  M. Ingelman-Sundberg,et al.  Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis. , 1995, The Journal of pharmacology and experimental therapeutics.

[3]  S. Joel,et al.  The analgesic activity of morphine-6-glucuronide. , 1992, British journal of clinical pharmacology.

[4]  A. Somogyi,et al.  Mu receptor binding of some commonly used opioids and their metabolites. , 1991, Life sciences.

[5]  G. Pasternak,et al.  Pharmacological characterization of morphine-6 beta-glucuronide, a very potent morphine metabolite. , 1989, The Journal of pharmacology and experimental therapeutics.

[6]  T. Hedner,et al.  Morphine-3-glucuronide may functionally antagonize morphine-6-glucuronide induced antinociception and ventilatory depression in the rat , 1992, Pain.

[7]  A. C. Dixon,et al.  The in vivo liberation of morphine from codeine in man. , 1954, Journal of Pharmacology and Experimental Therapeutics.

[8]  J. Hasselström,et al.  Morphine Pharmacokinetics and Metabolism in Humans , 1993, Clinical pharmacokinetics.

[9]  W. El,et al.  The metabolic fate of codeine in man. , 1955, The Journal of pharmacology and experimental therapeutics.

[10]  A. Rane,et al.  Ethylmorphine O‐deethylation cosegregates with the debrisoquin genetic metabolic polymorphism , 1992, Clinical pharmacology and therapeutics.

[11]  J. Svensson.  Determination of morphine, morphine-6-glucuronide and normorphine in plasma and urine with high-performance liquid chromatography and electrochemical detection , 1986 .

[12]  S. Sommer,et al.  Parameters affecting the yield of DNA from human blood. , 1987, Analytical biochemistry.

[13]  Maree T. Smith,et al.  Morphine-3-glucuronide--a potent antagonist of morphine analgesia. , 1990 .

[14]  C. Alm,et al.  Interindividual and interethnic differences in the demethylation and glucuronidation of codeine. , 1989, British journal of clinical pharmacology.

[15]  M. Elsohly,et al.  Morphine and Codeine in Biological Fluids: Approaches to Source Differentiation. , 1989, Forensic science review.

[16]  A. Rane,et al.  Human fetal and adult liver metabolism of ethylmorphine. Relation to immunodetected cytochrome P-450 PCN and interactions with important fetal corticosteroids. , 1989, Biochemical pharmacology.

[17]  J. Mørland,et al.  Different biotransformation of morphine in isolated liver cells from guinea pig and rat. , 1993, Biochemical pharmacology.

[18]  B. Tang,et al.  Variability of acetaminophen metabolism in Caucasians and Orientals. , 1992, Pharmacogenetics.

[19]  A. Rane,et al.  Determination of morphine, morphine-3-glucuronide and (tentatively) morphine-6-glucuronide in plasma and urine using ion-pair high-performance liquid chromatography. , 1982, Journal of chromatography.

[20]  G. Pasternak,et al.  Morphine-6-glucuronide, a potent mu agonist. , 1987, Life sciences.

[21]  A. Dickenson,et al.  The spinal antinociceptive actions of morphine metabolites morphine-6-glucuronide and normorphine in the rat , 1989, Brain Research.

[22]  U. Meyer,et al.  Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification , 1990, The Lancet.

[23]  A. Rane,et al.  N-demethylation of ethylmorphine in pregnant and non-pregnant women and in men: an evaluation of the effects of sex steroids. , 1992, British journal of clinical pharmacology.

[24]  M. Ingelman-Sundberg,et al.  Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[25]  J. Idle,et al.  The role of individual human cytochromes P450 in drug metabolism and clinical response. , 1992, Trends in pharmacological sciences.

[26]  B. Burchell,et al.  The enantioselective glucuronidation of morphine in rats and humans. Evidence for the involvement of more than one UDP-glucuronosyltransferase isoenzyme. , 1989, Biochemical pharmacology.

[27]  A. Christophersen,et al.  Morphine formation after intake of ethylmorphine. , 1992, Pharmacology & toxicology.

[28]  F. Gonzalez,et al.  Molecular genetics of the debrisoquin‐sparteine polymorphism , 1991, Clinical pharmacology and therapeutics.

[29]  D. Gavaghan,et al.  Oral morphine in cancer pain: influences on morphine and metabolite concentration , 1990, Clinical pharmacology and therapeutics.

[30]  P. Watkins,et al.  Heterogeneity of CYP3A isoforms metabolizing erythromycin and cortisol , 1992, Clinical pharmacology and therapeutics.